Acute pyelonephritis in adults: An update

Reviews and Research in Medical Microbiology

Volumn 14, Issue 4, 2003, Pages 119-127

  Horcajada, Juan P ^a   Smithson, Alex ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute pyelonephritis; Diagnosis; Pathogenesis; Review; Therapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFIXIME; CEFTAZIDIME; CEFTIBUTEN; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VIRULENCE FACTOR;

ACUTE PYELONEPHRITIS; ADULT; AGE DISTRIBUTION; ANTIBIOTIC SENSITIVITY; CLINICAL FEATURE; COMMUNITY CARE; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE SEVERITY; EARLY DIAGNOSIS; ELDERLY CARE; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; MALE; OUTCOMES RESEARCH; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCINTIGRAPHY; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 4143117798     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-200310000-00003     Document Type: Review

References (45)

1. Bergeron MG. Treatment of pyelonephritis in adults. Med Clin North Am 1995, 79:619-649.
2. Roberts FJ, Geere IW, Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis 1991, 13:34-46.
3. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JA. Urinary tract infection: self reported incidence and associated costs. Ann Epidemiol 2000, 10:509-515.
4. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, costs and prevention. Infect Control Hosp Epidemiol 1996, 17:552-557.
5. Hooton TM, Stamm WE. The vaginal flora and urinary tract infections. In: Warren JW, Mololey HLT (editors): Urinary tract infections: molecular pathogenesis and clinical management. Washington, DC: American Society of Microbiology Press; 1996:67-94.
6. Velasco M, Horcajada JP, Mensa J, Moreno-Martínez A, Vila J, Martinez JA, et al. Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis 2001, 33:1682-1686.
7. Kahlmeter G. The ECO*SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000, 46 (Suppl 1):15)-22.
8. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001, 32: 1162-1171.
9. Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999, 14:606-609.
10. Sotto A, De Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol 2001, 39:438-444.
11. Ena J, Amador C, Martínez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 1995, 153:117-120.
12. Vromen M, van der Ven AJ, Knols A, Stobberingh EE. Antimicrobial resistance patterns in urinay isolates from nursing home residents. Fifteen years of data reviewed. J Antimicrob Chemother 1999, 44:113-116.
13. Oelschlaeger TA, Dobrindt U, Hacker J. Virulence factors of uropathogens. Curr Opin Urol 2002, 12:33-36.
14. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000, 181: 261-272.
15. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin based systemic vaccination. Science 1997, 276:607-611.
16. Connell I, Agace W, Klemm P, Schembri M, Marild S, Svanborg C. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci USA 1996, 93:9827-9832.
17. Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate hosts defenses. Proc Natl Acad Sci USA 2000, 97:8829-8835.
18. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren S. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000, 19:2803-2812.
19. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001, 69:4572-4579.
20. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003, 301:105-107.
21. Wullt B, Bergsten G, Samuelsson M, Gebretsadik N, Hull R, Svanborg C. The role of P fimbriae for colonization and host response induction in the human urinary tract. J Infect Dis 2001, 183 (Suppl 1):43-46.
22. Johanson IM, Plos K, Marklund BI, Svanborg C. Pap, papG and prs DNA sequences in Escherichia coli from the fecal flora and the urinary tract. Microbiol Pathol 1993, 15:121-129.
23. Frendeus B, Wachtler C, Hedlund M, Fisher H, Samuelsson P, Svensson M, et al. Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation. Mol Microbiol 2001, 40:37-51.
24. Guyer DM, Gunther NW, Mobley HL. Secreted proteins and other features specific to uropathogenic Escherichia coli. J Infect Dis 2001, 183 (Suppl 1):32-35.
25. Ruiz J, Simon K, Horcajada JP, Velasco M, Barranco M, Roig G, et al. Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J Clin Microbiol 2002, 40: 4445-4449.
26. Vila J, Simon K, Ruiz J, Horcajada JP, Velasco M, Barranco M, et al. Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis 2002, 186:1039-1042.
27. Horcajada JP, Vila J, Moreno-Martínez A, Ruiz J, Martínez JA, Sánchez M, et al. Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J Antimicrob Chemother 2002, 49:55-59.
28. Shortliffe LM, McCue JD. Urinary tract infection at the age extremes: pediatrics and geriatrics. Am J Med 2002, 113 (Suppl 1):55-66.
29. Horcajada JP, Moreno I, Velasco M, Martínez JA, Moreno-Martínez A, Barranco M, et al. Community-acquired febrile urinary tract infection in diabetics could deserve a different management: a case-control study. J Intern Med 2003, 254: 280-286.
30. Mensa J, Gatell JM, Jiménez de Anta MT, Prats G, Domínguez-Gil A. Therapeutic Antimicrobial Guide. Acute Pyelonephritis. Barcelona: Masson; 2002.
31. Nosher JL, Tamminen JL, Amorosa JK, Kallich M. Acute focal bacterial nephritis. Am J Kidney Dis 1988, 11:36-42.
32. Dembry LM, Andriole VT. Renal and perirenal abscesses. Infect Clin North Am 1997, 11:663-680.
33. Griffin MD, Bergstralhn EJ, Larson TS. Renal papillary necrosis-a sixteen-year clinical experience. J Am Soc Neprhol 1995, 6:248-256.
34. Velasco M, Martinez JA, Moreno-Martinez A, Horcajada JP, Ruiz J, Barranco M, et al. Blood cultures in women with uncomplicated acute pyelonephritis: are they necessary? Clin Infect Dis 2003, 37:1127-1130.
35. Horcajada JP, Martínez JA, Moreno-Martínez A, Mensa J, Almela M, Soriano E. Predictive factors of the presence bacteremia in males with urinary tract infection. Med Clin (Barc) 1999, 112:734-735.
36. Andrews SJ, Brooks PT, Hanbury DC, King CM, Prendergast CM, Bostead GB, et al. Ultrasonography and abdominal radiography versus intravenous urograpby in investigation of urinary tract infection in men: prospective incident cohort study. BMJ 2002, 324:454-456.
37. Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T. Selective urological evaluation in men with febrile urinary tract infection. BJU Int 2001, 88:15-20.
38. Mateos JJ, Velasco M, Lomeña F, Horcajada JP, Setoain FJ, Martin F, et al. 111 Indium labelled leukocyte in detection of acute prostatitis. Nucl Med Commun 2002, 23:1137-1142.
39. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaefer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infection Disease Society of America (IDSA). Clin Infect Dis 1999, 29:745-758.
40. Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother 2002, 50: 945-952.
41. Sanchez M, Collvinent B, Miro O, Horcajada JP, Moreno A, Marco F, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomized controlled trial. Emerg Med J 2002, 19:19-22.
42. Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med 1999, 159:53-58.
43. Moreno-Martínez A, Mensa J, Martínez JA, Marco F, Vila J, Almela M, et al. Cefixime versus amoxicillin plus metilmicin in the treatment of community-acquired non-complicated acute pyelonephritis. Med Clin (Barc) 1998, 111:521-524.
44. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000, 283:1583-1590.
45. Mensa J, Moreno-Martínez A, Martínez JA, Marco F, Vila J, Horcajada JP, et al. Treatment of acute uncomplicated pyelonephritis (AUP): a randomized trial comparing 7 vs. 14-day therapy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 25-29, 1999 [abstract 613].